More recently, the combination of nivolumab and CTLA-4 inhibitor ipilimumab was shown to significantly enhance OS when compared to first-line chemotherapy in metastatic NSCLC, regardless of PD-L1 status [49]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.